Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +0.54% 46.50p 46.00p 47.00p 46.50p 46.25p 46.25p 159,131 08:14:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 95

Futura Medical Share Discussion Threads

Showing 17051 to 17074 of 17200 messages
Chat Pages: 688  687  686  685  684  683  682  681  680  679  678  677  Older
DateSubjectAuthorDiscuss
17/7/2019
10:33
indeed looks again, well bought on the dip...DYOR
qs99
17/7/2019
10:07
Solid bounce back after that slight retrace, next stop base camp at 80.
tiananmen
17/7/2019
09:58
Sole trader, You appear to be negative on this stock. ??? Do you hold? Or is that the reason for negativity? Many who held this stock a couple of years or so ago could be sitting on potential losses. However, as they say future performance doesn’t always correlate to historical performance. New drugs, new areas of medicine focus, different potentials. Who knows FUM May have learnt from past errors. If anyone is making any money on any stocks, investors as a whole should be pleased as we are all in the same game. There is so much negativity around especially with the threat of the nasty Marxists who are hoping to get into power. If anyone is doing well in any investment, good luck to them as it’s a middle finger salute to the Green Eye’d Monster philosophy of the Marxists 👍
utyinv
17/7/2019
09:56
shakey shakey :-)
ragnarr
17/7/2019
09:47
quite a few X 10,000 showing up on my screen....any views?
qs99
17/7/2019
09:47
Or is that the buyers returning? Blimey that was a quick response...let's see GLA
qs99
17/7/2019
09:45
hasn't really paused has it IMO over last month or so, so probably not surprising? I did think that the buyers were still there driving it up, but maybe not. Time for a breather? DYOR
qs99
17/7/2019
09:41
Wondered wether you would pop out from your rock again :- last prediction was down to 25p
ragnarr
17/7/2019
08:50
Stuffing Your Faces at the Trough Little Piggies? Be Fearful when Others are Greedy? FUM Up 780%+ Since beginning of Year - But... its going to the Moon, Right!?!! Phase 3 European Efficacy Study - estimated completion - end of Q4 2019 Phase 3 European Efficacy Study - Open Label EXTENSION - estimated completion - end of Q3 2020 Phase 3 SECOND (2nd) Efficacy Study - estimated completion end of Q4 2020 EARLIEST Regulatory Submission for EU Q2 2020 - US? Who knows? Don't forget another fund raise along the way. Just saying! P.S - BARDER is in Charge - he is a man that gets things done! ;-)
5oletrader
17/7/2019
08:16
well a nice blue opening anyway, GLA
qs99
17/7/2019
08:12
more to come today?
qs99
17/7/2019
07:48
I guess Zak Mir is looking at the energy of the rise in august 2016 when the shares moved from 20p to 90p in around one month. This time around we are 3 months away from phase 3 trials results. Charts are not gospel but can provide useful information about likely moves. 2016 was likely a dress rehearsal,now comes the main event.
j777j
17/7/2019
04:26
I was actually thinking leaks of a different type....good one though
tommyl1
17/7/2019
03:58
Ahh, you've heard about the incontinence side effect then.
glavey
16/7/2019
19:42
Great couple of days. Maybe some leaks from study participants as to how well it works? That would be nice.
tommyl1
16/7/2019
18:54
Well, he's a chartist, so to be taken with a pinch of salt. But many would have bought here because, effectively, it is going up, and 'every share price tells a story'. It should not be the only factor, clearly.
brucie5
16/7/2019
18:52
Everyone has some capability, influence and credibility - its just a matter of how much :-)
ragnarr
16/7/2019
17:46
I'm not being funny, but Zak Mir has no investment capability, influence or credibility. he's been unsuccessfully self promoting for over 20 years. don't think he has any insight, because he doesn't !
bg23
16/7/2019
16:36
I was buying these in the Spring when I was chilling in Morocco around 15p from memory, see no reason to sell, holding for 2-5 yrs.
ny boy
16/7/2019
16:19
Does look very strong buying, each time it gets sold down, up it goes again. Let's see what unfolds, but last 3 weeks right angled increase and doubling of share price suggests something worthwhile IMO! DYOR
qs99
16/7/2019
16:18
big buyer moping all these sells looks like stake building for take over
goldie40
16/7/2019
15:05
Zak Mir has just upped one month target for futura to 80p. GLA
j777j
16/7/2019
14:18
Perhaps the chart will let me knowLombards next move. Now that would be something!
wantage
16/7/2019
13:40
You like FUM ? Then you will love Diurnal Group (DNL.L) a brutally undervalued & undiscovered gem . Diurnal has a ridiculous low valuation of only £24 Million and over £11 million in cash , the company has already one Drug (Alkindi)approved in europe since last year ,NDA submission for US approval expected next quarter . They have another Drug called Chronocort for which they expect to submit the MAA to EMA for European approval by next quarter .Get some and enjoy the ride to 100p++ very soon thank me later Diurnal Group (DNL.L) Market Cap £25 Million Cash £11.5 Million Price 27p hxxps://www.diurnal.co.uk/non-healthcare-professionals/media/news/placing-open-offer-and-notice-of-general-meeting/ oFiling a Market Authorisation Application (MAA) for Chronocort® in Europe by end 2019; oFiling a New Drug Application (NDA) for Alkindi® in the US by end 2019; oContinuing the development of the European commercial organisation and roll-out of Alkindi® in Europe to maximise revenues; and oProgressing licensing discussions for Alkindi® and Chronocort® in the US and the rest of the world Martin Whitaker, PhD, Chief Executive Officer of Diurnal, commented: “Diurnal has continued to make strong progress across its business, including the successful launch of Alkindi® in Europe and confirmation of the regulatory paths for Chronocort® in Europe and Alkindi® in the US, where regulatory submissions are planned for Q4 2019. The funds raised will allow us to progress our vision of becoming a world-leading specialty pharma company in endocrinology, in particular to support the commercial infrastructure for the further roll-out of Alkindi® in Europe, paving the way for the expected future launch of Chronocort®, and to secure partnerships for Alkindi® and Chronocort® outside of Europe.”
ih_116147
Chat Pages: 688  687  686  685  684  683  682  681  680  679  678  677  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190822 09:05:22